30 results found.

Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck Clinical Trial using CC-115

Celgene Corporation - Recruiting 18 years or older.
- A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
CC-115

Malignant Gliomas Clinical Trial using CT-011

Hadassah Medical Organization - Recruiting 3 years to 90 years.
- A Phase I/ II Clinical Trial of CT-011 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme.
CT-011

Recurrent Supratentorial Glioblastoma Multiforme, GBM, or Gliobla Clinical Trial using Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)

Duke University - Recruiting 18 years or older.
- Dose-finding and Safety Study of PVSRIPO Against Recurrent Glioblastoma.
Live attenuated, oral (Sabin) serotype 1 poliovirus vaccine (PVSRIPO)

Glioblastoma Multiforme Clinical Trial using I-124-CLR1404

Cellectar Biosciences, Inc. - Recruiting 18 years or older.
- Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme.
I-124-CLR1404

Glioblastoma Multiforme Clinical Trial using ketogenic diet

Mid-Atlantic Epilepsy and Sleep Center, LLC - Recruiting 18 years to 65 years.
- Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study.
ketogenic diet

Malignant Neoplasms Brain Clinical Trial using RNA-loaded dendritic cell vaccine; basiliximab

Duke University - Recruiting 18 years or older.
- REGULATory T-Cell Inhibition With Basiliximab (Simulectr) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme.
RNA-loaded dendritic cell vaccine; basiliximab

Glioblastoma Multiforme Clinical Trial using Radiochemotherapy

Technische Universit„t Dresden - Recruiting 18 years or older.
- Observational Study of Impact of [11C]-Methionine PET/MRI as a Tool for Individual Tailoring Postoperative Radiochemotherapy for Patients With Glioblastoma Multiforme.
Radiochemotherapy

Glioblastoma Multiforme Clinical Trial using ALECSAT; Bevacizumab/Irinotecan

CytoVac A/S - Recruiting 18 years or older.
- An Open-labelled, Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured as Progression Free Survival Compared to Avastin/Irinotecan.
ALECSAT; Bevacizumab/Irinotecan

Glioblastoma Clinical Trial using Blood draw - biomarkers; MRI-guided Laser Heat Ablation (MLA); Doxorubicin

Washington University School of Medicine - Recruiting 18 years or older.
- A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme.
Blood draw - biomarkers; MRI-guided Laser Heat Ablation (MLA); Doxorubicin

Advanced Malignant Glioma, Anaplastic Astrocytomas, or Glioblasto Clinical Trial using AMG 595

Amgen - Recruiting 18 years or older.
- A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII).
AMG 595

Glioblastoma Multiforme, or Gliosarcoma Clinical Trial using AMG 102 with Avastin

Duke University - Recruiting 18 years or older.
- Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects With Recurrent Malignant Glioma.
AMG 102 with Avastin

Glioblastoma Multiforme Clinical Trial using TPI 287; Bevacizumab

Cortice Biosciences, Inc. - Recruiting 18 years or older.
- Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following Bevacizumab Alone.
TPI 287; Bevacizumab

Glioblastoma Multiforme Clinical Trial using NovoTTF-100A device; Temozolomide

NovoCure Ltd. - Recruiting 18 years or older.
- A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM..
NovoTTF-100A device; Temozolomide

Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligo Clinical Trial using Toca 511

Tocagen Inc. - Recruiting 18 years to 80 years.
- A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
Toca 511

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Na‹ve Patients With Recurrent Glioblastoma Multiforme.
anti-endoglin monoclonal antibody TRC105; bevacizumab; laboratory biomarker analysis; pharmacological study

Astrocytoma, Oligoastrocytoma, Mixed, Ganglioneuroma, Glioma, Gan Clinical Trial using Irinotecan; Bevacizumab; FDOPA-PET/MRI imaging

Washington University School of Medicine - Recruiting N/A to 21 years.
- Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study.
Irinotecan; Bevacizumab; FDOPA-PET/MRI imaging

Glioblastoma Multiforme Clinical Trial using Bevacizumab; BKM120

SCRI Development Innovations, LLC - Recruiting 18 years or older.
- Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II).
Bevacizumab; BKM120

Brain Cancer Clinical Trial using Temozolomide; Memantine; Mefloquine; Metformin

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- A Phase I lead-in to a 2x2x2 Factorial Trial of Dose Dense Temozolomide, Memantine, Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme.
Temozolomide; Memantine; Mefloquine; Metformin

Glioblastoma Multiforme Clinical Trial using ABT-414; Temozolomide; Whole Brain Radiation

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination With Radiation Plus Temozolomide or Temozolomide Alone for Subjects With Glioblastoma Multiforme.
ABT-414; Temozolomide; Whole Brain Radiation

Giant Cell Glioblastoma, Glioblastoma, or Gliosarcoma Clinical Trial using bevacizumab; temozolomide; laboratory biomarker analysis; immunohistochemistry staining method; microarray analysis; DNA methylation analysis

Jonsson Comprehensive Cancer Center - Recruiting 70 years or older.
- Phase II Study of Bevacizumab and Temozolomide in Elderly Patients With Newly-Diagnosed Glioblastoma.
bevacizumab; temozolomide; laboratory biomarker analysis; immunohistochemistry staining method; microarray analysis; DNA methylation analysis

Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 13 years or older.
- Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Leukapheresis

Glioma, Brain Cancer, Brain Tumor, Glioblastoma Multiforme, or Hi Clinical Trial using Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

University of Miami Sylvester Comprehensive Cancer Center - Recruiting 1 year to 30 years.
- A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors.
Dendritic Cell Vaccine; Tumor Lysate; Imiquimod; Punch Biopsy of the Skin; Leukapheresis

Glioblastoma Clinical Trial using Magnetic Resonance Imaging (MRI)

Medical University of South Carolina - Recruiting 18 years to 80 years.
- Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease.
Magnetic Resonance Imaging (MRI)

Brain and Central Nervous System Tumors Clinical Trial using dasatinib; temozolomide; placebo

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
dasatinib; temozolomide; placebo

Glioblastoma Multiforme, or Anaplastic Astrocytoma Clinical Trial using Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB

Weill Medical College of Cornell University - Recruiting 18 years or older.
- Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma.
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB

Glioblastoma Multiforme, or Anaplastic Astrocytoma Clinical Trial using Bevacizumab and Carboplatin

Weill Medical College of Cornell University - Recruiting 18 years or older.
- Phase I/II Trial Of Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory Glioblastoma Multiforme And Anaplastic Astrocytoma.
Bevacizumab and Carboplatin

Glioblastoma Multiforme/Anaplastic Astrocytoma Clinical Trial using temozolomide; radiation therapy; stereotactic radiotherapy

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Hypofraction Radiotherapy + Temozolomide in the Treatment of Patients With Glioblastoma Multiforme and Anaplastic Astrocytoma of the Brain.
temozolomide; radiation therapy; stereotactic radiotherapy

Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 Clinical Trial using Cilengitide

Northern Sydney and Central Coast Area Health Service - Recruiting 18 years or older.
- Phase 11 Study of Cilengitide in Combination With Concurrent Chemotherapy and Radiotherapy Followed by Protracted Daily Low Dose Temozolomide and Low Dose Procarbazine D1 - 20 in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Promoter Gene.
Cilengitide

GLIOBLASTOMA MULTIFORME, or Brain Neoplasm Clinical Trial

Washington University School of Medicine - Recruiting 18 years to 70 years.
- BIRN (Biomedical Informatics Research Network)Resources Facilitate the Personalization of Malignant Brain Tumor.

Glioblastoma Multiforme Clinical Trial using dynamic contrast enhanced magnetic resonance imaging

Yale University - Recruiting 18 years to 80 years.
- Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities.
dynamic contrast enhanced magnetic resonance imaging